Combination of Transarterial Radioembolization with Atezolizumab and Bevacizumab for Intermediate and Advanced Staged Hepatocellular Carcinoma: A Preliminary Report of Safety and Feasibility

Overview

Journal J Interv Med

Specialty General Medicine

Date 2024 Feb 5

PMID 38312131

Authors

Qian Yu

Yating Wang

Ethan Ungchusri

Mikin Patel

Divya Kumari

Thuong Van Ha

Anjana Pillai

Chih-Yi Liao

Osman Ahmed

Affiliations

Soon will be listed here.

Abstract

Purpose: The IMbrave150 Phase III trial demonstrated the superiority of atezolizumab and bevacizumab (Atezo/Bev) over sorafenib for unresectable hepatocellular carcinoma (HCC). The present study aims to evaluate the feasibility of TARE in combination with Atezo/Bev for the treatment of intermediate and advanced staged HCC.

Methods: A retrospective review at a single institution was performed between May 2021 and December 2022. Patients who received TARE using yttrium-90 (Y90) with concomitant or sequential Atezo/Bev systemic treatment were included. The following outcomes were retrieved: overall survival (OS), radiologic tumor response, progression-free survival, technical adverse events related to TARE, and toxicity based on the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0.

Results: Ten consecutive patients with intermediate (n = 4) and advanced stage HCC (n = 6) were treated with TARE and sequential/concomitant Atezo/Bev. Tumor control was achieved in all TARE-treated target lesions (100%). Overall disease progression occurred in 4 patients with PFS of 78.8% and 66.7% at 6- and 12- months, respectively. Two patients died at follow-up, with 6-month and 12-month OS rates of 90.0% and 77.1%, respectively. Three (75%) patients with intermediate stage disease were downstaged into Milan criteria. One patient developed grade 3 transaminitis and hypoglobulinemia, while Atezo/Bev was switched to Lenvatinib in another patient due to immunotherapy related myositis.

Conclusion: This study demonstrates the initial safety and feasibility of combined TARE with Atezo/Bev for intermediate/advanced stage HCC. Further prospective studies with larger sample sizes are warranted.

Citing Articles

Current Treatment Methods in Hepatocellular Carcinoma.

Krupa K, Fudalej M, Cencelewicz-Lesikow A, Badowska-Kozakiewicz A, Czerw A, Deptala A Cancers (Basel). 2024; 16(23).

PMID: 39682245 PMC: 11640602. DOI: 10.3390/cancers16234059.

Immune Checkpoint Inhibitors in the Pre-Transplant Hepatocellular Carcinoma Setting: A Glimpse Beyond the Liver.

Marzi L, Mega A, Turri C, Gitto S, Ferro F, Spizzo G Int J Mol Sci. 2024; 25(21).

PMID: 39519230 PMC: 11547112. DOI: 10.3390/ijms252111676.

Yttrium-90 radioembolization treatment strategies for management of hepatocellular carcinoma.

Hao K, Paik A, Han L, Makary M World J Radiol. 2024; 16(10):512-527.

PMID: 39494134 PMC: 11525828. DOI: 10.4329/wjr.v16.i10.512.

Blood MALT1 serves as a potential biomarker reflecting the response and survival of immune‑checkpoint‑inhibitor therapy in advanced hepatocellular carcinoma.

Ma W, Yue Y, Dong B, Wei L, Tian L Oncol Lett. 2024; 28(4):476.

PMID: 39161329 PMC: 11332575. DOI: 10.3892/ol.2024.14609.

Maximizing therapeutic outcomes in hepatocellular carcinoma: Insights into combinatorial strategies.

Ilhan Y, Ergun Y World J Gastrointest Oncol. 2024; 16(7):2888-2893.

PMID: 39072186 PMC: 11271765. DOI: 10.4251/wjgo.v16.i7.2888.

References

Yau T, Park J, Finn R, Cheng A, Mathurin P, Edeline J . Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2021; 23(1):77-90. DOI: 10.1016/S1470-2045(21)00604-5. View

Miller F, Vendrami C, Gabr A, Horowitz J, Kelahan L, Riaz A . Evolution of Radioembolization in Treatment of Hepatocellular Carcinoma: A Pictorial Review. Radiographics. 2021; 41(6):1802-1818. DOI: 10.1148/rg.2021210014. View

Zhan C, Ruohoniemi D, Shanbhogue K, Wei J, Welling T, Gu P . Safety of Combined Yttrium-90 Radioembolization and Immune Checkpoint Inhibitor Immunotherapy for Hepatocellular Carcinoma. J Vasc Interv Radiol. 2019; 31(1):25-34. DOI: 10.1016/j.jvir.2019.05.023. View

Finn R, Ryoo B, Merle P, Kudo M, Bouattour M, Lim H . Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2019; 38(3):193-202. DOI: 10.1200/JCO.19.01307. View

Binnewies M, Roberts E, Kersten K, Chan V, Fearon D, Merad M . Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018; 24(5):541-550. PMC: 5998822. DOI: 10.1038/s41591-018-0014-x. View

Finn R, Qin S, Ikeda M, Galle P, Ducreux M, Kim T . Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020; 382(20):1894-1905. DOI: 10.1056/NEJMoa1915745. View

Salem R, Johnson G, Kim E, Riaz A, Bishay V, Boucher E . Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study. Hepatology. 2021; 74(5):2342-2352. PMC: 8596669. DOI: 10.1002/hep.31819. View

Ruohoniemi D, Zhan C, Wei J, Kulkarni K, Aaltonen E, Horn J . Safety and Effectiveness of Yttrium-90 Radioembolization around the Time of Immune Checkpoint Inhibitors for Unresectable Hepatic Metastases. J Vasc Interv Radiol. 2020; 31(8):1233-1241. DOI: 10.1016/j.jvir.2020.04.029. View

Deipolyi A, Johnson C, Riedl C, Kunin H, Solomon S, Oklu R . Prospective Evaluation of Immune Activation Associated with Response to Radioembolization Assessed with PET/CT in Women with Breast Cancer Liver Metastasis. Radiology. 2022; 306(1):279-287. PMC: 9772064. DOI: 10.1148/radiol.220158. View

10.

Dalakas M . Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol. 2010; 6(3):129-37. DOI: 10.1038/nrrheum.2010.2. View

11.

Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca A, Pageaux G . Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017; 18(12):1624-1636. DOI: 10.1016/S1470-2045(17)30683-6. View

12.

Ahmed O, Yu Q, Patel M, Hwang G, Pillai A, Liao C . Yttrium-90 Radioembolization and Concomitant Systemic Gemcitabine, Cisplatin, and Capecitabine as the First-Line Therapy for Locally Advanced Intrahepatic Cholangiocarcinoma. J Vasc Interv Radiol. 2022; 34(4):702-709. DOI: 10.1016/j.jvir.2022.12.017. View

13.

Herbst R, Soria J, Kowanetz M, Fine G, Hamid O, Gordon M . Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515(7528):563-7. PMC: 4836193. DOI: 10.1038/nature14011. View

14.

Hwang W, Pike L, Royce T, Mahal B, Loeffler J . Safety of combining radiotherapy with immune-checkpoint inhibition. Nat Rev Clin Oncol. 2018; 15(8):477-494. DOI: 10.1038/s41571-018-0046-7. View

15.

Gajewski T, Schreiber H, Fu Y . Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013; 14(10):1014-22. PMC: 4118725. DOI: 10.1038/ni.2703. View

16.

Rivoltini L, Bhoori S, Camisaschi C, Bergamaschi L, Lalli L, Frati P . Y-radioembolisation in hepatocellular carcinoma induces immune responses calling for early treatment with multiple checkpoint blockers. Gut. 2022; 72(2):406-407. PMC: 9872224. DOI: 10.1136/gutjnl-2021-326869. View

17.

Wallin J, Bendell J, Funke R, Sznol M, Korski K, Jones S . Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun. 2016; 7:12624. PMC: 5013615. DOI: 10.1038/ncomms12624. View

18.

Ahmed O, Patel M, Masrani A, Chong B, Osman M, Tasse J . Assessing Intra-arterial Complications of Planning and Treatment Angiograms for Y-90 Radioembolization. Cardiovasc Intervent Radiol. 2017; 40(5):704-711. DOI: 10.1007/s00270-016-1555-3. View